Gomes Tara, Campbell Tonya, Tadrous Mina, Mamdani Muhammad M, Paterson J Michael, Juurlink David N
Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
ICES, Toronto, Ontario, Canada.
Pharmacoepidemiol Drug Saf. 2021 Mar;30(3):379-389. doi: 10.1002/pds.5180. Epub 2020 Dec 18.
As clinical practice moves towards more judicious opioid prescribing, physicians require information on how to safely initiate opioids. The objective of this study was to examine the association between initial opioid prescription characteristics and risks of harm and long-term use.
We conducted a population-based retrospective cohort study among Ontario residents newly dispensed an opioid for pain between July 2013 and March 2016. The primary exposure was the average daily opioid dose dispensed at initiation (in milligram morphine equivalents; MME), with secondary exposures including the initial prescription's duration and formulation. The primary outcome was fatal or non-fatal opioid overdose. A secondary analysis studied continued opioid use for at least 1 year.
Among the 2 021 371 individuals meeting our inclusion criteria, 1121 (0.56 per 1000 person-years) experienced an opioid overdose within 1 year and 64 013 (3.17%) continued treatment for at least 1 year. Higher initial daily dose, longer prescription duration, and receipt of a long-acting formulation at initiation were significantly associated with higher hazard of overdose. Compared to daily doses of 20 MME or lower, initial doses exceeding 200 MME daily were associated with a particularly high hazard of overdose (aHR 2.97, 95% confidence interval [CI] 1.62 to 5.44). In the secondary analysis, there were similar associations between initial dose, duration, and formulation and long-term use.
Although the absolute risk of an opioid overdose within the first year of prescription opioid use is low, better alignment of opioid initiation practices with guidelines may reduce opioid-related harm.
随着临床实践朝着更合理地开具阿片类药物处方的方向发展,医生需要有关如何安全启动阿片类药物治疗的信息。本研究的目的是探讨初始阿片类药物处方特征与伤害风险及长期使用之间的关联。
我们在2013年7月至2016年3月期间新开具阿片类药物用于止痛的安大略省居民中进行了一项基于人群的回顾性队列研究。主要暴露因素是开始时每日开具的阿片类药物平均剂量(以毫克吗啡当量计;MME),次要暴露因素包括初始处方的持续时间和剂型。主要结局是致命或非致命的阿片类药物过量。一项次要分析研究了阿片类药物持续使用至少1年的情况。
在符合我们纳入标准的2021371名个体中,1121人(每1000人年0.56人)在1年内发生了阿片类药物过量,64013人(3.17%)持续治疗至少1年。初始每日剂量较高、处方持续时间较长以及开始时接受长效剂型与较高的过量风险显著相关。与每日剂量20 MME或更低相比,每日初始剂量超过200 MME与特别高的过量风险相关(调整后风险比2.97,95%置信区间[CI] 1.62至5.44)。在次要分析中,初始剂量、持续时间和剂型与长期使用之间也存在类似的关联。
尽管在处方阿片类药物使用的第一年内发生阿片类药物过量的绝对风险较低,但使阿片类药物启动实践更好地符合指南可能会减少阿片类药物相关伤害。